CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
We will continue to provide comprehensive analysis and reports about therapeutic antibody licensing deals between Chinese biopharma and overseas companies. In this third business report on this topic, we focus on licensing deals closed in 2022.
Posted on March 9, 2023
9 minutes read
The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit will be virtually held from 23-25, March 2021
less than a minute read
Read Story10% off registration fee for CAS members when registering for 2021 CHI Meetings
less than a minute read
Read StoryThe Chinese Antibody Society (CAS) and the organizing committee of the Antibody Engineering & Therapeutics (AET) conference have entered into a collaboration
1 minute read
Read StoryThe Chinese Antibody Society and Cambridge Healthtech Institute Announce Strategic Partnership
2 minutes read
Read Story